Latest News
Quidel Receives Preliminary Contract Leading to Definitive Agreement for $71 Million Under NIH’s RADx-ATP Program to Accelerate the Expansion of Its Manufacturing Capacity for Sofia® SARS-CoV-2 Antigen Detection Test for Rapid Diagnosis of COVID-19
Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that Quidel has entered into a preliminary letter contract with the National Institute...
Quidel In The News
NBC News Los Angeles - New coronavirus test gives results in minutes, not days
EXTRA TV - EXTRA's Billy Bush takes COVID-19 test
MSN - Quidel's game-changing test key to reopening economy?
Today Show - FDA authorizes rapid antigen test
Wall Street Journal - FDA to grant emergency use status for first coronavirus antigen test by Quidel
Bloomberg - FDA authorizes Quidel's antigen test
New York Times - FDA approves first antigen test for detecting coronavirus
Careers
Are you a determined, optimistic, team player? Quidel is looking for talented innovators who want to be part of revolutionizing medical diagnostics.
Support
To place orders, get assistance with shipments, pricing or contract administration view our Customer Support page.
Visit our Technical Support page to get help with product specifications, supporting docs or general support issues.
For Package Inserts and supporting docs visit our Document Search Tool
NEW: Visit ConnectMe.quidel.com for help connecting your Quidel Instruments to the cloud, including the Virena surveillance system.
Register at MyQuidel.com to download and install the latest Software Updates, Assay and testing capabilities for your Quidel Instruments.